Self-Assembling Peptide Scaffold for Synthetic Hapten Vaccines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing subunit vaccines are time-consuming, labor-intensive, and costly, requiring recombinant protein expression in hosts like bacteria, yeast, and mammalian cells.
Innovation Solution
A method involving self-assembling monomer peptides that form dimers, trimers, or hexamers, which include T-cell epitopes and can be conjugated with haptens, used to synthetically produce vaccines through solid phase peptide synthesis, eliminating costly and time-consuming steps of traditional vaccine development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant protein expression in hosts (bacteria, yeast, mammalian cells) is used to produce subunit vaccines, then vaccine production can be achieved through established methods, but the process becomes time-consuming, labor-intensive, and costly
Solution Approach 1:
The patent extracts and utilizes only the essential immunogenic components (epitopes) from pathogens, removing the need for complex recombinant protein expression systems. By identifying and synthesizing only the critical T-cell and B-cell epitopes, the vaccine development process eliminates time-consuming steps involving host cell culture, protein purification, and extensive characterization, thereby reducing development time while maintaining vaccine effectiveness
Solution Approach 2:
The patent creates simplified synthetic copies of the essential immunogenic elements rather than producing full-length recombinant proteins. By synthesizing peptide epitopes directly through solid-phase peptide synthesis (SPPS), the method produces functional equivalents that replicate the immune-stimulating properties of native proteins without requiring complex biological expression systems, thus accelerating development while ensuring reliability
2Ease of manufacture
If recombinant protein expression methods are used for subunit vaccine production, then established production protocols can be followed, but the process becomes labor-intensive and costly
Solution Approach 1:
The patent replaces complex biological manufacturing systems (recombinant expression in living cells) with a simplified chemical synthesis approach (solid-phase peptide synthesis). This substitution eliminates labor-intensive steps such as cell culture maintenance, transformation, protein expression optimization, and purification from living systems, thereby reducing manual intervention while increasing production efficiency through standardized chemical protocols
Solution Approach 2:
The patent employs short peptide sequences that can be rapidly synthesized and discarded or regenerated as needed, replacing the need for maintaining complex, expensive recombinant expression systems. The synthetic epitopes can be produced on-demand through standardized chemical synthesis, eliminating ongoing costs associated with host cell lines, media, and purification infrastructure, thus improving productivity while simplifying manufacture
3Reliability
If traditional vaccine development processes are followed, then comprehensive immunogenicity testing can be performed, but the process becomes time-consuming and costly
Solution Approach 1:
The patent segments the complex immunogenicity assessment into distinct, testable components by identifying and synthesizing specific T-cell and B-cell epitopes separately. This segmentation allows for focused immunogenicity testing of individual epitope components rather than requiring comprehensive testing of full-length recombinant proteins, thereby maintaining reliable assessment of immune response while reducing the time and cost associated with evaluating entire protein structures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for a more efficient and cost-effective production of vaccines by synthesizing all components synthetically, inducing a robust immune response with reduced immunogenicity and minimal extraneous sequences, enabling scalable and affordable vaccine production.
Implementation Method 1
monomer peptides comprising two or more heptads that self-assemble into a dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, nanomer, or decamer
Data Source
AI summary
The present disclosure describes a peptide scaffold for producing vaccines. The peptide scaffold includes a peptide that self-assembles into a hapten carrier (hC) includes amphipathic alpha-helices. The peptide includes heptad repeats following a specific pattern. The hC further includes hapten or an agent conjugated to it, and optionally the hC includes one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions including immunogenic compositions including the hapten-hC or agent-hC conjugate.